Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Gu
12 Novembro 2009 - 11:52AM
PR Newswire (US)
BALTIMORE, Nov. 12 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , an oncology
drug development company with a predictive preclinical platform
aimed at accelerating the development and enhancing the value of
oncology drugs, has announced that two of its studies regarding its
application in oncology drug development and personalized medicine
have been selected for a poster and oral presentation at the
upcoming AACR-EORTC conference in Boston. A poster will be
presented by Dr. Elizabeth Bruckheimer, Champions' Vice President
for Scientific Operations, which will detail the Biomerk
Tumorgraft(TM) platform and its characterization. Together the
results demonstrate that by maintaining the fundamental genotypic
features of the original tumor along with the stromal and cancer
stem cell components, the Biomerk Tumorgraft enables identification
of the most promising development path for a compound in terms of
indication, drug combination, and target patient populations. The
platform also has the potential to identify gene pathways of
response and resistance as well as prognostic molecular biomarkers.
The banking and characterization efforts are performed in
collaboration with South Texas Accelerated Research Therapeutics
(START). "The predictive power of the Biomerk Tumorgraft platform
is very exciting," said Dr. Bruckheimer. "Application of our models
to translational drug development is demonstrating great promise in
streamlining the development path of our biotech and pharma
partners by giving them a more focused, accelerated and higher
probability translational path in clinical trials. Additionally, we
are using our platform to build our own oncology pipeline which we
expect to yield improved clinical development success rates. We
believe that this platform will continue to change the way in which
oncology drugs are developed, and oncology patients are treated."
In collaboration, Dr. Manuel Hidalgo, Professor of Oncology at the
Universidad CEU San Pablo, Director of the Centro Integral
Oncologia "Clara Campal" and Director of the Clinical Research
Program at CNIO all in Madrid, Spain and Champions' Chief Scientist
will present data regarding prolonged clinical responses from
Tumorgraft recommended treatments in patients with refractory
advanced cancer, and the ability of the Tumorgraft platform to
discover novel predictive biomarkers. He will show the correlation
between Tumorgraft response in mice and clinical activity in
patients, demonstrating a perfect correlation of sensitivity and
response. Data Presentations: -- From Mice to Men: Guiding Cancer
Treatment through Personalized Tumorgraft(TM) Models Results in
Prolonged Clinical Responses in Patients with Refractory Advanced
Cancers and Discovery of Novel Predictive Biomarkers will be
presented on Tuesday November 17th from 4:30 - 5:30 PM during the
Proffered Paper Session. -- Establishment and Characterization of
Primary Human Biomerk Tumorgraft Models: Application to Oncology
Drug Development will be presented on Monday November 16th from
12:30 - 2:30 PM and 5:30 - 7:30 PM during the poster session
(Abstract #A25). For more information regarding Champions
Biotechnology's growing business and recent news, please visit
http://www.championsbiotechnology.com/. About Champions
Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the
development of advanced preclinical platforms and tumor specific
data to enhance and accelerate the value of oncology drugs. The
Company's Preclinical Platform is a novel approach based upon the
implantation of primary human tumors in immune deficient mice
followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. Early studies suggest
that unlike traditional xenografts, these Tumorgrafts closely
reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. Champions
Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic
candidates. As drugs progress through early stage development, the
Company plans to sell, partner or license them to pharmaceutical
and/or biotechnology companies, as appropriate. The Company also
offers its predictive preclinical platform and tumor specific data
to physicians for personalized patient care and to companies for
evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.
http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/
This press release contains "forward-looking statements" (within
the meaning of the Private Securities Litigation Act of 1995) that
inherently involve risk and uncertainties. Champions Biotechnology
generally uses words such as "believe," "may," "could," "will,"
"intend," "expect," "anticipate," "plan," and similar expressions
to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-K for the fiscal year ended April
30, 2009 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected
in the forward-looking statements are reasonable, they relate only
to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity,
performance or achievements may not meet these expectations. The
Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Champions
Biotechnology's expectations, except as required by law. CONTACT:
The Investor Relations Group, Inc. James Carbonara +1-212-825-3210
DATASOURCE: Champions Biotechnology, Inc. CONTACT: James Carbonara,
The Investor Relations Group, Inc., +1-212-825-3210 Web Site:
http://www.championsbiotechnology.com/
Copyright